(Q73297940)

English

A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 10

scientific article published on 01 March 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human Interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100–300 CD4+ t cells (English)

1 reference

10.1016/S1521-6616(02)00038-4

https://api.crossref.org/works/10.1016/S1521-6616(02)00038-4

26 December 2023

randomized controlled trial

1 reference

based on heuristic

inferred from title

CD4 lymphocyte count

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706405

26 December 2023

1 reference

10.1016/S1521-6616(02)00038-4

https://api.crossref.org/works/10.1016/S1521-6616(02)00038-4

26 December 2023

Susan L Koletar

5

object named as

Susan L Koletar

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Norman Markowitz

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Haig Donabedian

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Carl Yoshizawa

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Anne-Marie Duliege

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Gwendolyn Fyfe

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Alberdina W. de Boer

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706405

26 December 2023

H. Clifford Lane

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706405

26 December 2023

Louis D. Saravolatz

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706405

26 December 2023

Ronald T. Mitsuyasu

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12706405

26 December 2023

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12706405

26 December 2023

publication date

1 March 2003

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

full work available at URL

https://api.elsevier.com/content/article/PII:S1521661602000384?httpAccept=text/xml

1 reference

10.1016/S1521-6616(02)00038-4

https://api.crossref.org/works/10.1016/S1521-6616(02)00038-4

26 December 2023

https://api.elsevier.com/content/article/PII:S1521661602000384?httpAccept=text/plain

1 reference

10.1016/S1521-6616(02)00038-4

https://api.crossref.org/works/10.1016/S1521-6616(02)00038-4

26 December 2023

Clinical Immunology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

106

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

188-196

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

The impact of highly active antiretroviral therapy on HIV-specific immune function

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of opportunistic disease in an HIV-infected urban clinical cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6616%2802%2900038-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1521-6616(02)00038-4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12706405%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73297940&oldid=2037160155"